Alpha Cognition Inc. (ACOG) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$8.49

From 52W high−12.51%

Volume169037.00

Market cap$185.77M

P/E (TTM)—

P/S (TTM)12.2x

Div yield—

Key dataNov 4, 2026

Open

$8.49

From 52W high

−12.51%

Volume

169037.00

Market cap

$185.77M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.3x

P/E (TTM)

—

RSI (14)

43.0

MomentumView details →

1D Return

+4.02%

YTD Return

+27.69%

SummaryUpdated Jun 1, 2026

Alpha Cognition Inc. (NASDAQ:ACOG) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Vancouver, Canada. The company was formerly known as Crystal Bridge Enterprises Inc. before changing its name in March 2021. Alpha Cognition focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company successfully transitioned from a pre-revenue clinical-stage entity to a commercial-stage company in 2025 with the launch of its flagship product ZUNVEYL for treating mild-to-moderate Alzheimer's disease.

Ask drillr about Alpha Cognition Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.3x

EV/Sales

9.5x

P/S (TTM)

12.2x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

89.89%

Net Margin

−153.61%

EBITDA Margin

−180.15%

ROE (TTM)

−44.26%

ROA (TTM)

−36.33%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+232.74%

EPS YoY

+31.77%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+42.08%

EBITDA YoY

−82.49%

MomentumView details →

1D Return

+4.02%

YTD Return

+27.69%

1Y Return

+41.16%

RSI (14)

43.0

vs 50D SMA

−6.19%

vs 200D SMA

+15.46%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

8.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

−2.00%

Beats (12Q)

4/12

Next Q EPS Est

−$0.28

Avg Surprise (4Q)

6.72%

Rev Surprise

36.86%

Financials snapshotView financials →

Revenue (TTM)

15.26M

Net Income (TTM)

−23.44M

Op. CF (TTM)

−30.91M

Next earningsNov 11, 2026 →

Latest newsMore news →

Alpha Cognition announced that it will report its third-quarter 2026 financial results and provide a business update on November 11, 2026, after market close.2d ago

The United States Patent and Trademark Office published Alpha Cognition’s patent application for a process to prepare benzgalantamine and its salts.23d ago

Similar companies

Apogee Acquisition Corp UnitsAACPU Inflection Point Acquisition Corp.GOW JAB Acquisition Corp. I Units Cons of 1 Sh -A- + 1 Red Wt + 1 RtATLQU Newbury Street II Acquisition CorpNTWOU Breeze Acquisition Corp. IIBREZ Ampercap Acquisition Co.APMC Find similar companies →

Latest newsMore news →

Alpha Cognition announced that it will report its third-quarter 2026 financial results and provide a business update on November 11, 2026, after market close.2d ago The United States Patent and Trademark Office published Alpha Cognition’s patent application for a process to prepare benzgalantamine and its salts.23d ago Alpha Cognition Inc. announced initial results from the CONVERGE real-world evidence evaluation of ZUNVEYL (benzgalantamine) use in long-term care, focusing on 180-day titration and concomitant medication patterns.35d ago